Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.40 |
| ▸ | FDPS | P14324 | 4/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9785162 | 0.94 | FDPS (0.36) | ACE2SMPD1FDPSZDHHC7PLA2G2A | |
| SCHEMBL958471 | 0.94 | FDPS (0.36) | ACE2SMPD1FDPSZDHHC7PLA2G2A | |
| SCHEMBL7948595 | 0.87 | TSHR (0.34) | FDPS | |
| SCHEMBL9254795 | 0.87 | TSHR (0.34) | FDPS | |
| SCHEMBL9633869 | 0.84 | BLM (0.41) | — | |
| SCHEMBL3741705 | 0.82 | FDPS (0.52) | ACE2SMPD1FDPSLAP3 | |
| SCHEMBL11688776 | 0.81 | CYP3A4 (0.40) | SMPD1FDPSZDHHC7PLA2G2AGPR84 | |
| SCHEMBL28945792 | 0.79 | ACE2 (0.59) | ACE2FDPSGPR84 | |
| SCHEMBL28945753 | 0.79 | ACE2 (0.59) | ACE2FDPSGPR84 | |
| SCHEMBL9633958 | 0.78 | FDPS (0.46) | ACE2SMPD1FDPSZDHHC7PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015238-A1 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015238-A1 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES | PTGFR, PTGIS, PTGIR | ACE2 2200/4885SMPD1 2337/4885FDPS 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.